• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Prestige Consumer Healthcare Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    1/6/25 8:00:30 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBH alert in real time by email
    false 0001295947 0001295947 2025-01-06 2025-01-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): January 6, 2025

     

    PRESTIGE CONSUMER HEALTHCARE INC.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware 001-32433 20-1297589
    (State or Other Jurisdiction of
    Incorporation)
    (Commission File Number) (IRS Employer Identification No.)

     

    660 White Plains Road, Tarrytown, New York 10591

    (Address of Principal Executive Offices) (Zip Code)

     

    (914) 524-6800

    (Registrant's telephone number, including area code)

     

    (Former Name or Former Address, if Changed Since Last Report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered or to be registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common stock, par value $0.01 per share PBH New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging Growth Company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

     

    On January 6, 2025, Prestige Consumer Healthcare Inc. (the “Company”) announced that the Company’s Chief Financial Officer, Christine Sacco, age 49, has also been appointed Chief Operating Officer, effective January 6, 2025. A copy of the press release announcing Ms. Sacco’s expanded role is attached hereto as Exhibit 99.1 and incorporated herein by reference.

     

    Christine Sacco was appointed to the position of Chief Financial Officer for the Company in September 2016. Ms. Sacco joined the Company from Boulder Brands, Inc., a health and wellness food manufacturer, where she served as the Chief Financial Officer and Treasurer from January 2012 to January 2016 and Vice President and Controller from January 2008 to January 2012, including Principal Accounting Officer from January 2011 to March 2012. From October 2002 until January 2008, she held positions of increasing financial responsibility with Alpharma, Inc., a global specialty pharma company, where she last held the position of Vice President, Treasurer. Ms. Sacco began her career with Ernst & Young and worked for five years in the Audit and Assurance group. She holds a B.S. in accounting from St. Thomas Aquinas College and has been a licensed CPA.

     

    In connection with this expanded role, Ms. Sacco will receive an annual base salary of $700,000, be eligible for target annual cash incentive of 75% of her base salary and be eligible to receive annual equity awards under our Long-Term Incentive Plan with a targeted award value of $1,575,000 allocated sixty percent (60%) of the targeted equity award value to performance stock units, and forty percent (40%) to restricted stock units. In addition, Ms. Sacco received a time-based restricted stock unit (“RSU”) retention award with an aggregate value of $1,575,000. The retention award RSUs granted to Ms. Sacco cliff vest in full, four years after the date of grant, subject to Ms. Sacco’s continued employment.

     

    There are no other arrangements or understandings between Ms. Sacco and any other person pursuant to which she was appointed to the positions described in this Current Report on Form 8-K, there are no family relationships between Ms. Sacco and any director or officer of the Company, and Ms. Sacco is not a party to any transaction that requires disclosure under Item 404(a) of Regulation S-K.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d)       Exhibits.

     

    See Exhibit Index immediately following the signature page.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: January 6, 2025 PRESTIGE CONSUMER HEALTHCARE INC.
         
      By: /s/ William P’Pool
        William P’Pool
        Sr. Vice President, General Counsel and Corporate Secretary

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit   Description
         
    99.1   Press Release dated January 6, 2025 announcing Chief Financial Officer Christine Sacco’s expanded role (furnished only).
         
    104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).

     

     

     

    Get the next $PBH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBH

    DatePrice TargetRatingAnalyst
    12/9/2024$90.00Buy → Neutral
    Sidoti
    6/21/2024$65.00 → $93.00Neutral → Buy
    DA Davidson
    11/17/2022$71.00Buy
    Canaccord Genuity
    5/10/2022$65.00 → $70.00Hold → Buy
    Jefferies
    5/9/2022$63.00Perform → Outperform
    Oppenheimer
    3/11/2022$156.00 → $142.00Outperform
    BMO Capital
    11/15/2021$61.00 → $63.00Neutral
    DA Davidson
    11/5/2021$123.00 → $126.00Sector Perform
    RBC Capital
    More analyst ratings

    $PBH
    SEC Filings

    See more
    • SEC Form 10-K filed by Prestige Consumer Healthcare Inc.

      10-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)

      5/9/25 6:06:00 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)

      5/8/25 6:04:33 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Prestige Consumer Healthcare Inc.

      SCHEDULE 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

      2/7/25 7:43:30 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Prestige Consumer downgraded by Sidoti with a new price target

      Sidoti downgraded Prestige Consumer from Buy to Neutral and set a new price target of $90.00

      12/9/24 9:05:37 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer upgraded by DA Davidson with a new price target

      DA Davidson upgraded Prestige Consumer from Neutral to Buy and set a new price target of $93.00 from $65.00 previously

      6/21/24 7:05:28 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Prestige Consumer with a new price target

      Canaccord Genuity initiated coverage of Prestige Consumer with a rating of Buy and set a new price target of $71.00

      11/17/22 7:23:24 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

      Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, wh

      5/8/25 7:09:10 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

      Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, which

      5/8/25 6:00:00 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and Year-End Earnings Results

      TARRYTOWN, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 fourth quarter and year-end earnings release on Thursday, May 8, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10

      4/10/25 5:00:00 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

      SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

      2/14/24 10:11:25 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

      SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

      2/14/24 7:09:49 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Prestige Consumer Healthcare Inc. (Amendment)

      SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

      2/13/24 5:12:15 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Lombardi Ronald M. covered exercise/tax liability with 2,305 shares, decreasing direct ownership by 0.66% to 346,529 units (SEC Form 4)

      4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

      5/9/25 5:46:21 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Marketing & Sales Mekhail Adel covered exercise/tax liability with 457 shares, decreasing direct ownership by 2% to 20,908 units (SEC Form 4)

      4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

      5/9/25 5:44:53 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CFO & COO Sacco Christine was granted 7,775 shares and covered exercise/tax liability with 990 shares, increasing direct ownership by 13% to 58,465 units (SEC Form 4)

      4/A - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

      5/9/25 5:43:10 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    Leadership Updates

    Live Leadership Updates

    See more
    • Better For You Wellness Announces Results from Its February 5, 2022, Board of Directors Meeting

      Better For You Wellness Establishes Strategic Advisory Committee with Industry Leaders and MoreColumbus, Ohio--(Newsfile Corp. - February 10, 2022) - Better For You Wellness, Inc. (OTCQB:BFYW) ("Better For You Wellness" or the "Company"), an Ohio-based company focused on the rapidly-growing $1.5T wellness industry, is pleased to announce the results of the Meeting of the Board of Directors that took place on February 5, 2022, via video conference (the "Board Meeting"). The seven members of the Company's Board of Directors (the "Board") include Ian James, Stephen Letourneau, Montel Williams, Christina Jefferson, Joseph Watson, David Deming, and Dr. Nicola Finley, MD.Establishment of Strategic

      2/10/22 3:58:00 PM ET
      $LEAF
      $PBH
      $SPTN
      EDP Services
      Technology
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBH
    Financials

    Live finance-specific insights

    See more
    • UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

      Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, wh

      5/8/25 7:09:10 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings

      Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal 2025; Adjusted fiscal 2025 Diluted EPS of $4.52 grew 7.4% versus adjusted prior yearReduced leverage to 2.4x at year-end driven by strong free cash flow and EBITDA growthInitial fiscal 2026 organic revenue growth and Diluted EPS outlook of approximately 1% to 2% and $4.70 to $4.82, respectively TARRYTOWN, N.Y., May 08, 2025 (GLOBE NEWSWIRE) --  Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2025. "We are very pleased with our fiscal year results, which

      5/8/25 6:00:00 AM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prestige Consumer Healthcare to Release Fiscal 2025 Fourth Quarter and Year-End Earnings Results

      TARRYTOWN, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 fourth quarter and year-end earnings release on Thursday, May 8, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10

      4/10/25 5:00:00 PM ET
      $PBH
      Biotechnology: Pharmaceutical Preparations
      Health Care